Last reviewed · How we verify

Celecoxib and aspirin — Competitive Intelligence Brief

Celecoxib and aspirin (Celecoxib and aspirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal anti-inflammatory drug (NSAID) combination. Area: Cardiovascular / Rheumatology.

phase 3 Non-steroidal anti-inflammatory drug (NSAID) combination COX-1 and COX-2 (cyclooxygenase enzymes) Cardiovascular / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Celecoxib and aspirin (Celecoxib and aspirin) — Takeda. This combination uses celecoxib (a selective COX-2 inhibitor) and aspirin (a non-selective COX inhibitor) together to reduce inflammation and pain through complementary inhibition of cyclooxygenase enzymes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Celecoxib and aspirin TARGET Celecoxib and aspirin Takeda phase 3 Non-steroidal anti-inflammatory drug (NSAID) combination COX-1 and COX-2 (cyclooxygenase enzymes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal anti-inflammatory drug (NSAID) combination class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celecoxib and aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-and-aspirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: